Handover of the extension notice to the DigiMed Bayern flagship project. f.l.t.r.: Verena Heidel (Project Manager, Deutsches Herzzentrum München), Dr. med. Veronika Sanin (Vroni study management, Deutsches Herzzentrum München) , Prof. Dr. Dieter Kranzmüller (Chairman of the Board of Directors Leibniz-Rechenzentrums), Dr. Jens Wiehler (Managing Director, DigiMed Bayern), Dr. med. Fabian Starnecker (Project Leader, HerzFit-App, Deutsches Herzzentrum München), Prof. Dr. med. Heribert Schunkert (Medical Director, Deutsches Herzzentrum München & Scientific Director, DigiMed Bayern), Prof. Dr. Horst Domdey (Managing Director BioM Biotech Cluster Development GmbH), Klaus Holetschek (Minister of State for Health and Care, StMGP), Dr. Jörg Traub (Project Manager Technologie & Director Gesundheit, Bayern Innovativ GmbH), Prof. Dr. Annette Peters (Director Institute of Epidemiology, Helmholtz Munich), Tina Engelhardt (Financial processing I Project Management Bavaria, Bayern Innovativ GmbH). © BioM

Digitisation of medicine is advancing: Holetschek extends flagship project "DigiMed Bayern - for the medicine of the future"

Martinsried, 12 September 2022 - The flagship project "DigiMed Bayern - for the medicine of the future" is being extended by one year. Bavaria's Minister of Health, Klaus Holetschek, personally handed over the extension notice to the managing BioM Biotech Cluster Development GmbH last Friday in the presence of top-class DigiMed Bayern partners from science and hospitals. DigiMed Bayern aims to prevent heart attacks and strokes and stands for data-based personalised medicine - using the widespread disease of atherosclerosis as an example.

The pandemic has shown how important science is in fighting crises. People with cardiovascular diseases have suffered particularly from COVID-19. In Bavaria alone, about 50,000 people died of cardiovascular diseases in 2020, about 6,500 from heart attacks, according to the Bavarian Heart Report. Prevention is the best protection: both to avoid the viral infection and to survive it in good health.

Please find the complete press release here.


 

DigiMed Bayern for the Medicine of the Future

P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient healthcare.
DigiMed Bayern's goal is to guide Bavaria with a flagship project into this medicine of the future.

ABOUT DigiMed Bayern

This slot is intended for displaying content of the external provider (https://www.youtube-nocookie.com/). Please be aware that this content as well as the processing of your user data when clicking on this link is outside of bio-m.org's responsibility and potentially not subject to the General Data Protection Regulation anymore. Manage details and settings for cookies and third party providers

The flagship P4-medicine project DigiMed Bayern was launched at the end of 2018 with more than € 20 million funding by the Bavarian State Ministry of Health and Care. DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.

Main goals of DigiMed Bayern

  • Using the case of atherosclerosis, a first analysis of comprehensive data sets is carried out in the context of digital medicine of the future. All those involved in the Bavarian health care system should benefit directly: the prediction for coronary heart disease (CHD) and stroke should be made more accurate in the short term, and preventive treatment should be improved. In the medium to long term, improvements in diagnosis and therapy are pursued. The population-wide identification of familial hypercholesterinemia as an exemplary risk factor for atherosclerosis should be sustainably improved.
  • Through concrete implementation measures, the technical, legal and social possibilities and limitations of P4 medicine are identified, promoted, and documented. This encompasses a proactive multi-directional information exchange with all those involved in health with a focus on systemic development.
  • Resulting findings and structures can be built upon in the health system, in research and in the economy, and can be transferred to other diseases. In particular, it is intended to create an exemplary and transferable integrated digital infrastructure.
  • Aim is to substantially develop Bavaria as a location for P4 medicine, including its international perception and global networking.

Project flyer

funded by


Scientific Management


Executive Management